CARDIOVASCULAR AND ICU
Cardiovascular disease (CVD) is a class of diseases that involve the heart or blood vessels. Cardiovascular disease includes coronary artery diseases (CAD) such as angina and myocardial infarction (commonly known as a heart attack).[2] Other CVDs include stroke, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, heart arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, thromboembolic disease, and venous thrombosis.
Rapibloc®
300 mg vial: powder for solution for infusion; 1 vial per pack
20mg /2mL ampoule: concentrate for solution for injection; 5 ampoules per pack
Active Pharmaceutical Ingredient: landiolol hydrochloride
Pharmacotherapeutic group: Beta-blocking agents, selective
Indication:
300 mg vial: powder for solution for infusion; 1 vial per pack
20mg /2mL ampoule: concentrate for solution for injection; 5 ampoules per pack
Active Pharmaceutical Ingredient: landiolol hydrochloride
Pharmacotherapeutic group: Beta-blocking agents, selective
Indication:
- Landiolol hydrochloride is indicated for supraventricular tachycardia and for rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short acting agent is desirable.
- Landiolol hydrochloride is also indicated for non-compensatory sinus tachycardia where, in the physician’s judgment the rapid heart rate requires specific intervention.
- Landiolol is not intended for use in chronic settings
Esmocard®
2500 mg vial: powder for concentrate for solution for infusion Esmolol hydrochloride; 1 vial per pack
100 mg /10 ml vial: solution for injection; 5 vials per pack
Active Pharmaceutical Ingredient: esmolol hydrochloride
Pharmacotherapeutic group: Beta-blocking agents, selective
Indication:
2500 mg vial: powder for concentrate for solution for infusion Esmolol hydrochloride; 1 vial per pack
100 mg /10 ml vial: solution for injection; 5 vials per pack
Active Pharmaceutical Ingredient: esmolol hydrochloride
Pharmacotherapeutic group: Beta-blocking agents, selective
Indication:
- Esmolol hydrochloride is indicated for supraventricular tachycardia (except for pre-excitation syndromes) and for the rapid control of the ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short-acting agent is desirable.
- Esmolol hydrochloride is also indicated for tachycardia and hypertension occurring in the perioperative phase and non-compensatory sinus tachycardia where, in the physician’s judgement the rapid heart rate requires specific intervention.
Empressin®
40 I.E./2 ml solution for injection; 10 ampoules per pack
Active Pharmaceutical Ingredient: Argipressin
Pharmacotherapeutic group: Vasopressin and analogues
Indication:
for the treatment of catecholamine refractory hypotension following septic shock in patients older than 18 years. A catecholamine refractory hypotension is present if the mean arterial blood pressure cannot be stabilized to 65 – 75 mmHg despite adequate volume substitution and application of catecholamine.
40 I.E./2 ml solution for injection; 10 ampoules per pack
Active Pharmaceutical Ingredient: Argipressin
Pharmacotherapeutic group: Vasopressin and analogues
Indication:
for the treatment of catecholamine refractory hypotension following septic shock in patients older than 18 years. A catecholamine refractory hypotension is present if the mean arterial blood pressure cannot be stabilized to 65 – 75 mmHg despite adequate volume substitution and application of catecholamine.